OKUR vs PATH · P/E 72, $76.6M cap vs P/E 19, rev $1.61B
OnKure Therapeutics, Inc. (OKUR) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
OnKure Therapeutics, Inc. (OKUR) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported OKUR revenue for 2024-12-31 was $0. Net income was -$52.7M. OKUR currently screens at market cap $76.6M and trailing P/E 71.8.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
OKUR currently screens at market cap $76.6M and trailing P/E 71.8. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the OKUR and PATH stock pages for the full models.
Not investment advice.